


## PHARMACEUTICAL 2023



## UNITED THERAPEUTICS Corp Rank 47 of 446





## PHARMACEUTICAL 2023



## UNITED THERAPEUTICS Corp Rank 47 of 446

The relative strengths and weaknesses of UNITED THERAPEUTICS Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UNITED THERAPEUTICS Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 84% points. The greatest weakness of UNITED THERAPEUTICS Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 246%, being 203% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	3,380,300
Cost of Goods Sold	151,600
Intangible Assets	0
Liabilities, Current	343,200
Liabilities, Non-Current	104,600
Other Assets	1,802,700
Other Compr. Net Income	-32,500
Other Expenses	705,400
Other Liabilities	800,000
Other Net Income	-29,100
Other Revenues	1,936,300
Property and Equipment	861,500
Research and Development	322,900
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	6,044,500
Liabilities	1,247,800
Expenses	1,179,900
Revenues	1,936,300
Stockholders Equity	4,796,700
Net Income	727,300
Comprehensive Net Income	711,050
Economic Capital Ratio	246%

